Search Results

You are looking at 241 - 250 of 384 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Horacio Asbun, Andrew Bain, Stephen W. Behrman, Al B. Benson III, Ellen Binder, Dana B. Cardin, Charles Cha, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Mary Dillhoff, Efrat Dotan, Cristina R. Ferrone, Jeffrey Hardacre, William G. Hawkins, Joseph Herman, Andrew H. Ko, Srinadh Komanduri, Albert Koong, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Eileen M. O'Reilly, Jorge Obando, Sushanth Reddy, Courtney Scaife, Sarah Thayer, Colin D. Weekes, Robert A. Wolff, Brian M. Wolpin, Jennifer Burns, and Susan Darlow

neutropenia, fatigue, and neuropathy. Development of peripheral neuropathy was associated with longer treatment duration and greater treatment efficacy. 57 Updated results of the MPACT trial show that long-term survival is possible with gemcitabine plus

Full access

Updates in HER2-Positive and Triple-Negative Breast Cancers

Presented by: Melinda L. Telli and William J. Gradishar

these were small patient subsets. 25 Although neutropenia can be an adverse effect, growth factors can help manage this, he added. PARP Inhibitors in TNBC The NCCN Guidelines “call out” patients with BRCA mutations as candidates for 2 approved

Full access

NCCN Task Force Report: Breast Cancer in the Older Woman

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer

older patients with breast cancer undergoing certain types of chemotherapy regimens. 21 , 118 Supportive care measures include therapies to minimize chemotherapy-related neutropenia and anemia. A meta-analysis of randomized studies evaluating primary

Full access

Durable Response to PD-1 Blockade in a Patient With Metastatic Pancreatic Undifferentiated Carcinoma With Osteoclast-Like Giant Cells

Robert J. Besaw, Adrienne R. Terra, Grace L. Malvar, Tobias R. Chapman, Lauren M. Hertan, and Benjamin L. Schlechter

-fluorouracil/oxaliplatin/leucovorin with intermittent treatment delays related to neutropenia and Clostridioides difficile infection, CT imaging revealed substantial progression of the pancreatic mass, now measuring 13.0 × 8.5 cm. The patient was then

Full access

Small Cell Lung Cancer

Gregory P. Kalemkerian, Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura Chow, Robert J. Downey, Leena Gandhi, Apar Kishor P. Ganti, Ramaswamy Govindan, John C. Grecula, James Hayman, Rebecca Suk Heist, Leora Horn, Thierry M. Jahan, Marianna Koczywas, Cesar A. Moran, Harvey B. Niell, Janis O'Malley, Jyoti D. Patel, Neal Ready, Charles M. Rudin, and Charles C. Williams Jr.

aspirates and biopsies may be indicated in select patients with nucleated red blood cells on peripheral blood smear, neutropenia, or thrombocytopenia and no other evidence of metastatic disease. Bone marrow involvement as the only site of extensive

Full access

Prevention and Early Treatment of Opportunistic Viral Infections in Patients With Leukemia and Allogeneic Stem Cell Transplantation Recipients

Michael Angarone and Michael G. Ison

-associated mortality in allogeneic stem cell transplant recipients . Transplantation 1998 ; 66 : 1330 – 1334 . 52. Salzberger B Bowden RA Hackman RC . Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of

Full access

Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report

Eugene R. Przespolewski, Jeffrey Baron, Farshid Kashef, Kai Fu, Sheila N. Jani Sait, Francisco Hernandez-Ilizaliturri, and James Thompson

comanagement of her CML and CLL. She has tolerated both imatinib and venetoclax very well with only mild leukopenia, anemia, neutropenia, and nausea managed with ondansetron. At the time of writing, her response to venetoclax therapy is unknown because

Full access

Improving Health Equity and Reducing Disparities in Pediatric and Adolescent/Young Adult Oncology: In Support of Clinical Practice Guidelines

Justine M. Kahn and Melissa Beauchemin

. Blood 2011 ; 117 : 2596 – 2603 . 10.1182/blood-2010-05-285379 21079154 32. Wright JD , Neugut AI , Ananth CV , Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes . JAMA Intern

Full access

Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non–Small Cell Lung Cancer

John A. Sharp, Daniel Jones, Julia K. Rotow, Panos M. Fidias, Erin Bertino, and Dwight H. Owen

she continues to receive after 9 months on treatment. Notable adverse effects include transient grade 3 neutropenia without fever and not requiring growth factor support, and grade 1 thrombocytopenia without bleeding and not requiring transfusions

Full access

Updates in the Treatment of Metastatic Colorectal Cancer

Presented by: Midhun Malla, Katrina S. Pedersen, and Aparna R. Parikh

representation was very limited; (3) PFS was significantly improved: 5.6 versus 2.4 months (HR, 0.44; 95% CI, 0.36–0.54); and (4) the safety profile was manageable, with neutropenia, nausea, and anemia being comparable or slightly higher in terms of any